After Hemophilia Deal, UniQure Sees Zolgensma As Model For Huntington’s Gene Therapy

Focused On Long-Term Gene Therapy Leadership

 
• By Andrew McConaghie
uniQure
uniQure had been tipped as a top M&A target for 2020

More from Business

More from Scrip